News

Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028. Speaking dur

Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance that reins in more aggressive valuation assumptions while still recognizing the early stage profile of Ocugen’s pipeline. As you read on, you will see how this updated narrative, and the data behind it, can help you track Ocugen’s evolving story. Analyst Price Targets don't always capture the full...

Ocugen’s latest analyst update comes with no change in its price target, leaving existing expectations intact for now. With no new analyst commentary accompanying this update, investors are left to interpret the steady price target in the context of their own view on the stock. In the sections that follow, you will see how to track these kinds of updates so you can keep up with the evolving narrative around Ocugen. Stay updated as the Fair Value for Ocugen shifts by adding it to your...

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Ocugen, Inc. (NASDAQ:OCGN) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment […]

In early May 2026, Ocugen reported Q1 2026 results showing revenue of US$1.53 million with a larger quarterly net loss of US$19.18 million, and completed a US$115 million private offering of 6.75% Convertible Senior Notes due 2034, using part of the proceeds to repay an existing term loan. Alongside these developments, Ocugen highlighted progress in its retinal gene therapy programs, including positive Phase 2 data for OCU410 and advancement of late-stage trials that underpin its...

Ocugen (NASDAQ:OCGN) used its first-quarter 2026 earnings call to highlight progress across its retinal gene therapy pipeline and to outline a strengthened balance sheet following a newly announced financing. Convertible notes offering and cash runway outlook Chairman, CEO, and Co-founder Dr. Shank

Ocugen Inc. (NASDAQ:OCGN) is one of the best biotech penny stocks to buy in 2026. On April 1, Ocugen completed dosing ahead of schedule in its Phase 2/3 GARDian3 pivotal clinical trial for OCU410ST, a first-in-class modifier gene therapy for Stargardt disease. The trial reached its enrollment target of 63 participants in less than 9 […]

Ocugen’s latest analyst update keeps the central fair value estimate at US$11.57, while published price targets from different firms span US$10, US$12 and US$22. That spread reflects contrasting views on the company’s gene therapy pipeline, with some analysts focusing on recent OCU410 and OCU400 data and BLA timelines, and others stressing execution, safety and financing risks. Looking ahead, you will see how this mix of steady fair value, widely ranged targets and new clinical milestones is...

Ocugen (OCGN) has drawn fresh investor attention after releasing full Phase 2 ArMaDa data for OCU410, showing a 46% reduction in macular lesion growth at 12 months and no therapy related serious adverse events. See our latest analysis for Ocugen. Despite the recent ArMaDa update, Ocugen’s 1 day share price return of 5.08% and 7 day return of 13.85% sit against a 21.74% year to date gain and a very large 1 year total shareholder return. This hints that enthusiasm around its gene therapy...

Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.

In April 2026, Ocugen, Inc. reported full Phase 2 ArMaDa trial results for OCU410 in geographic atrophy secondary to dry age-related macular degeneration, showing a 46% reduction in macular lesion growth at 12 months for medium and high doses versus control and no therapy-related serious adverse events across Phase 1 and 2. An interesting aspect of the update is that OCU410 uses a gene-agnostic modifier gene therapy approach, aiming to address dry AMD regardless of the specific underlying...